These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

801 related items for PubMed ID: 20482673

  • 21. Patterns of melastatin mRNA expression in melanocytic tumors.
    Deeds J, Cronin F, Duncan LM.
    Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
    [Abstract] [Full Text] [Related]

  • 22. Ex vivo quality-switched ruby laser irradiation of cutaneous melanocytic lesions: persistence of S-100-, HMB-45- and Masson-positive cells.
    Kopera D, Hohenleutner U, Stolz W, Landthaler M.
    Dermatology; 1997 Nov; 194(4):344-50. PubMed ID: 9252755
    [Abstract] [Full Text] [Related]

  • 23. TRPM1 (melastatin) expression is an independent predictor of overall survival in clinical AJCC stage I and II melanoma patients.
    Brożyna AA, Guo H, Yang SE, Cornelius L, Linette G, Murphy M, Sheehan C, Ross J, Slominski A, Carlson JA.
    J Cutan Pathol; 2017 Apr; 44(4):328-337. PubMed ID: 27987328
    [Abstract] [Full Text] [Related]

  • 24. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
    Nazarian RM, Prieto VG, Elder DE, Duncan LM.
    J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. CRTC3, a sensor and key regulator for melanogenesis, as a tunable therapeutic target for pigmentary disorders.
    Yoo H, Lee HR, Kim KH, Kim MA, Bang S, Kang YH, Kim WH, Song Y, Chang SE.
    Theranostics; 2021 Apr; 11(20):9918-9936. PubMed ID: 34815795
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors.
    King R, Googe PB, Weilbaecher KN, Mihm MC, Fisher DE.
    Am J Surg Pathol; 2001 Jan; 25(1):51-7. PubMed ID: 11145251
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas.
    Xu X, Chu AY, Pasha TL, Elder DE, Zhang PJ.
    Am J Surg Pathol; 2002 Jan; 26(1):82-7. PubMed ID: 11756773
    [Abstract] [Full Text] [Related]

  • 38. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression.
    Krengel S, Grotelüschen F, Bartsch S, Tronnier M.
    J Cutan Pathol; 2004 Jan; 31(1):1-7. PubMed ID: 14675278
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis.
    King R, Weilbaecher KN, McGill G, Cooley E, Mihm M, Fisher DE.
    Am J Pathol; 1999 Sep; 155(3):731-8. PubMed ID: 10487831
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.